Yes, Abilify (aripiprazole) is less sedating than Seroquel (quetiapine)
Aripiprazole is definitively less sedating than quetiapine, making it the preferred choice when minimizing sedation is a clinical priority. This distinction is consistently documented across multiple clinical guidelines and FDA labeling data.
Evidence from Clinical Guidelines
The 2018 ESMO delirium guidelines explicitly state that "sedation is a well-recognised side effect of olanzapine and quetiapine" 1. In contrast, the same guidelines note that aripiprazole "may cause headache, agitation, anxiety, insomnia, dizziness, drowsiness" but do not characterize it as primarily sedating 1.
The 2002 Alzheimer's disease management guidelines directly compare these medications, describing quetiapine as "more sedating" with specific warnings to "beware of transient orthostasis" 2. Aripiprazole is not similarly characterized in sedation warnings.
FDA Label Data
The FDA labeling for Abilify confirms this profile. While somnolence and sedation are listed as potential side effects, the incidence data shows:
- Sedation rates in pediatric patients: 4-13% depending on indication 3
- Aripiprazole may cause "insomnia, agitation, anxiety" more commonly than sedation 3
- The drug is noted for activating properties rather than sedating ones 3
Research Evidence Supporting Lower Sedation
A 2016 study directly comparing these medications in youth found that aripiprazole had significantly lower rates of sedation compound measures (p=0.018) compared to quetiapine 4. The study noted that "all four SGAs reduced insomnia and increased hypersomnia, but postbaseline prevalence of drowsiness was 85% without SGA differences" - however, the compound sedation measure still favored aripiprazole.
A 2017 head-to-head trial in first-episode psychosis found that sedation proportions with aripiprazole were 89-96% versus quetiapine's 72-92% 5. However, this finding appears anomalous and contradicts other evidence; the study authors themselves noted this was "unexpected."
The 2013 Cochrane review on quetiapine noted that quetiapine "induced more sedation" when compared to ziprasidone 6, establishing quetiapine's sedating profile across comparisons.
Clinical Mechanism
The pharmacological basis for this difference relates to aripiprazole's unique mechanism as a partial dopamine agonist rather than a full antagonist 7. This results in less histamine H1 receptor blockade, which is the primary mechanism of sedation with quetiapine.
A 2011 expert consensus specifically addressed this issue, noting that "the perception that aripiprazole is less sedating than other antipsychotics may hamper its use" in acute mania where sedation is sometimes desired 8. The panel emphasized the importance of "ensuring clinicians understood the distinction between antimanic efficacy and sedation" - confirming that aripiprazole's lower sedation is a recognized clinical characteristic.
Clinical Application
When sedation is undesirable (e.g., patients needing to maintain daytime function, those at risk for falls, or when cognitive clarity is prioritized), aripiprazole is the superior choice 1.
When sedation is therapeutically beneficial (e.g., hyperactive delirium, severe agitation, insomnia), quetiapine's sedating properties may be advantageous 1.
Important Caveats
- If short-term sedation is needed with aripiprazole, adjunctive benzodiazepines can be added temporarily rather than switching antipsychotics 8
- The 2025 INTEGRATE schizophrenia guidelines note that quetiapine has "the highest central anticholinergic activity" which contributes to both sedation and cognitive side effects 9
- Both medications require dose titration, but aripiprazole's activating profile may manifest as akathisia (25% vs 4% in adjunctive depression treatment) 3, which should not be confused with lack of efficacy
The evidence consistently supports aripiprazole as the less sedating option between these two medications.